High proliferation is associated with inferior outcome in male breast cancer patients
| Autor: | Leif Bergkvist, Marie-Louise Fjällskog, Ingrid Hedenfalk, Sten Thorstenson, Ida Johansson, Cecilia Nilsson, Cecilia Ahlin, Anthoula Koliadi |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Pathology Mitotic index Cyclin A Cyclin B Kaplan-Meier Estimate Breast Neoplasms Male Pathology and Forensic Medicine Young Adult Cyclin D1 Breast cancer Internal medicine Biomarkers Tumor Mitotic Index medicine Humans Aged Cell Proliferation Neoplasm Staging Aged 80 and over Tissue microarray biology business.industry Cancer Middle Aged medicine.disease Immunohistochemistry Tissue Array Analysis Male breast cancer biology.protein Female Neoplasm Grading business |
| Zdroj: | Modern Pathology. 26:87-94 |
| ISSN: | 0893-3952 |
| Popis: | Assessment of proliferation is important in female breast cancer and individual treatment decisions are based upon its results, especially in the lumina! subgroups. Gene expression analyses fail to group male breast cancer into the intrinsic subgroups previously established in female breast cancer. Even though proliferation has been shown to divide male breast cancer into molecular subgroups with different prognoses, the clinical importance of proliferation markers has not yet been elucidated. Previous studies in male breast cancer have demonstrated contradictory results regarding the prognostic impact of histological grade and Ki-67, parameters strongly associated with proliferation. The aim of the present project was to study proliferation in male breast cancer by assessing other proliferation-related markers viz. cyclins A, B, D1 and mitotic count. A total of 197 male breast cancer cases with accessible paraffin-embedded material and outcome data were investigated. Immunohistochemical stainings were performed on tissue microarrays. Kaplan-Meier estimates and the Cox proportional regression models were used for survival analyses with breast cancer death as the event. The subset of patients with high expression of cyclin A (hazard ratio (HR) 3.7; P=0.001) and B (HR 2.7; P=0.02) demonstrated a poorer survival. Furthermore, high mitotic count was associated with an increased risk of breast cancer death (HR 2.5; P=0.01). In contrast, cyclin D1 overexpression was predictive of better breast cancer survival (HR 0.3; P=0.001). In conclusion, high levels of cyclin A and B expression and an elevated mitotic count result in a two to threefold higher risk for breast cancer death, whereas cyclin D1 overexpression halves the risk. The clinical utility of these proliferation markers needs further elucidation. Modern Pathology (2013) 26, 87-94; doi:10.1038/modpathol.2012.145; published online 24 August 2012 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|